All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Real-world study on efficacy and safety of ide-cel in older patients with RRMM
Bookmark this article
|
Data from a real-world study on the efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM) were published in Blood Advances by Kalariya et al.1 The study included safety and efficacy data from older patients (≥65 years) who were ineligible for the KarMMa study (NCT03361748). |
| Key learnings: |
|
Overall, 156 patients were included, of which 81 were aged <65 years and 75 were aged ≥65 years. Among the older patients, 66.7% were frail and 77.3% did not meet the eligibility criteria for the KarMMa study. |
|
The best overall response rate (ORR) and complete response rate with ide-cel were comparable among both older and younger patients (86.7% vs 84% and 56% vs 54.3%, respectively). |
|
A numerically higher median progression-free survival (PFS) and overall survival (OS) was observed among older patients.
|
|
The incidences of any grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were higher in older patients. However, the incidences of Grade ≥3 CRS and ICANS were comparable between older and younger patients. CRS:
ICANS:
|
|
Despite the higher prevalence of frailty and geriatric characteristics, such as polypharmacy, comorbidities, and organ dysfunction, the efficacy and safety data of ide-cel in older patients were comparable to younger patients. |
|
The data highlighted the feasibility of ide-cel in older patients with RRMM, and the potential for broader adoption in clinical practice. |
- Kalariya N, Hildebrandt M, Hansen D, et al. Clinical outcomes after idecabtagene vicleucel in older multiple myeloma patients: A multicenter real-world experience. Blood Advances. Online ahead of print. DOI: 10.1182/bloodadvances.2024013540
Your opinion matters
0 votes - 57 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox